LEADS BIOLABS-B (09887.HK): Six Research Abstracts Accepted for ESMO Congress 2026, Including Two Proffered Paper Presentations and LBA Eligibility

NewTimeSpace · 2026/07/13 16:46 · By Xuran Lin

NewTimeSpace News: Leads Biolabs-B(09887.HK) announced on 13 July that six research outcomes have been accepted for presentation at ESMO Congress 2026, comprising two Proffered Paper oral presentations, four poster displays and Late-Breaking Abstract (LBA) qualification, covering extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer and relapsed/refractory multiple myeloma. The Company stated the selections reflect international recognition of its clinical data and pipeline value and demonstrate sustained innovation capabilities in tumour immunotherapy. Previously, a study of VELIXIN™ for first-line non-small cell lung cancer was selected for oral presentation at WCLC. Investors are reminded of uncertainties relating to product development and commercialisation.

NewTimeSpace News: On 13 July 2026, LEADS BIOLABS-B(09887.HK) released a voluntary announcement. Six latest research results from the Company have been accepted for ESMO Congress 2026. Among them, two were selected for top-tier Proffered Paper oral presentations and four will be showcased as posters, covering indications including extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer and relapsed/refractory multiple myeloma. The Company has also obtained eligibility for Late-Breaking Abstract (LBA).

ESMO Congress ranks among the world’s most influential oncology academic conferences. The 2026 event will be held in Madrid, Spain from 23 October to 27 October. Proffered Paper sessions represent the highest presentation tier, reserved for studies with the greatest clinical significance and scientific innovation.

Earlier, the Company disclosed that clinical research of VELIXIN™ for first-line non-small cell lung cancer was selected for oral presentation at the World Conference on Lung Cancer (WCLC). The Company commented that simultaneous acceptance of multiple studies validates international academia’s recognition of the quality of its clinical data and pipeline value, and highlights continuous innovation strength in tumour immunotherapy. The Company cautions there can be no assurance regarding successful development and eventual commercial launch of its product candidates.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

LEADS BIOLABS-B 09887.HK ESMO